Bristol Myers Squibb, one of the world's largest biopharmaceutical companies, has been a subject of intense debate because its shares are inexpensive yet face a major patent cliff. With the stock trading near $67, the $80 mark has emerged as a widely discussed objective: it represents the highest price target among major Wall Street firms, including a Buy-rated target from UBS that was raised from $70 to $80.
That $80 level is meaningful on two fronts. First, it sits roughly 19% above the recent share price, a realistic but non-trivial distance that would require genuine catalysts rather than ordinary day-to-day volatility. Second, it would push the stock decisively past its 52-week high of about $68.64 and into territory not seen in recent years.
Bristol Myers Squibb has posted a notable recovery over the past year, climbing from a 52-week low near $42.52 to recent trading around $67. The rally reflects improving investor confidence in the company's "growth portfolio" of newer medicines, which has been expanding while its legacy drugs decline. The company derives roughly 70% of sales from the United States, giving it significant exposure to domestic pricing and policy dynamics.
Fundamentally, the stock trades at a forward price-to-earnings (P/E) multiple near 10, well below the broader market and many pharmaceutical peers. It also offers a forward dividend yield around 3.8%, backed by a long record of consistent payouts that spans more than five decades.
Several factors support the case that the $80 target is within reach. The most important is the pipeline. Investors are closely tracking milvexian, an experimental anticoagulant being developed for atrial fibrillation, with pivotal Phase 3 data expected before the end of 2026. Because milvexian could help offset revenue lost as Eliquis faces generic competition, a positive readout is widely viewed as the single biggest catalyst for the shares.
Beyond milvexian, the company's oncology franchise — anchored by Opdivo — and newer products such as Cobenfy and mezigdomide continue to grow. Recent positive Phase 3 results for mezigdomide in multiple myeloma reinforced confidence in the pipeline's depth. If the growth portfolio sustains its momentum and clinical data continue to land favorably, analysts such as Bank of America, Barclays, Guggenheim, Piper Sandler, and Argus have published targets ranging from roughly $66 to $75, with the most optimistic voices pointing toward $80.
Valuation also leaves room for expansion. Bulls argue that even modest multiple expansion from a low single-digit forward P/E, combined with steady earnings, could carry the stock meaningfully higher — especially given the dividend yield that attracts income-focused investors.
The principal risk is Eliquis, Bristol Myers Squibb's best-selling product. As its patent protection erodes and generic competition emerges, the company faces a genuine "patent cliff" that could pressure revenue and earnings. A large legacy portfolio that is already in decline amplifies this challenge, and the company carries substantial debt (around $45 billion) that constrains flexibility.
Not all analysts are convinced the stock can reach $80 — or even hold its current level. Morgan Stanley maintains a Sell-equivalent stance with a $40 target, reflecting a far more cautious view of the pipeline's ability to replace lost Eliquis sales. Regulatory setbacks, disappointing trial data, or slower-than-expected uptake of new drugs would all undermine the bullish thesis.
From a technical analysis perspective, the $68–$69 area is the immediate supply zone, since it corresponds to the 52-week high and represents the last major hurdle before the stock can establish a new uptrend leg. A sustained close above that level would open the path toward the round-number psychological zones at $70 and then $75. The $80 price target itself functions as the next major resistance level beyond $75.
On the downside, the $60–$62 region — near recent moving averages — and the $57–$58 area serve as notable support levels. As long as the stock holds above these zones, the longer-term uptrend remains intact even if progress toward $80 is gradual.
Wall Street's consensus on Bristol Myers Squibb sits in "Moderate Buy" territory, but the distribution is unusually wide. The average 12-month analyst price target is roughly $66, essentially in line with the current price, while individual targets span from $40 at the low end to $80 at the high end. This divergence underscores the binary nature of the investment debate: the outcome depends heavily on whether the pipeline delivers.
Critically, the $80 level is not the consensus expectation — it is the optimistic case. That means investors should view it as a scenario-dependent outcome rather than a baseline forecast.
For traders seeking to monitor changing conditions in Bristol Myers Squibb and thousands of other securities, Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to traditional analysis. The product uses artificial intelligence to continuously scan stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, track existing positions, and identify shifting market trends more efficiently than manual monitoring allows.
The $80 stock price target for Bristol Myers Squibb is ambitious but not implausible. It would require the company's growth portfolio to keep accelerating, favorable late-stage clinical data — particularly for milvexian — and enough multiple expansion to lift the shares roughly 19% from current levels. The low valuation and attractive dividend provide a supportive backdrop, while the 52-week high near $68.64 offers an immediate technical milestone to watch.
At the same time, the risks are substantial. The Eliquis patent cliff, a declining legacy business, and a heavy debt load all weigh on the outlook, and the fact that $80 represents the Street's highest target — not its consensus — should temper expectations. Investors should monitor upcoming clinical readouts, new-product sales trends, and whether the stock can decisively clear its prior high before concluding that the $80 objective is becoming more probable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.16% | ||
| PFE - BMY | 58% Loosely correlated | +0.32% | ||
| AMGN - BMY | 57% Loosely correlated | +1.92% | ||
| NVS - BMY | 55% Loosely correlated | +6.04% | ||
| GSK - BMY | 53% Loosely correlated | +0.82% | ||
| ABBV - BMY | 51% Loosely correlated | +1.39% | ||
More | ||||